Preventive cardiologist, lipidologist, and clinical researcher @UCSDHealth @UCSDMedSchool
Joined October 2014
- Tweets532
- Following282
- Followers1.4K
- Likes1.3K
Pinned Tweet
🔥Immune-mediated inflammatory diseases & dyslipidemia intersect, drive CV risk
🏃♀️💊Targeted prevention can make a difference
@DrMichaelShapir
@atvbahajournals
@garshick @Bweber04 @CBallantyneMD @DrMarthaGulati @JohnKastelein @mdavidsonmd @lipiddoc
ahajournals.org/eprint/8J736…
Michael Wilkinson retweeted
In our new @masala_study analysis @JACCJournals, Lp(a) levels vary among disaggregated South Asian groups, but the association between Lp(a) levels and outcomes does not.
@UCSDCardiology @UCSDCardFellows
sciencedirect.com/science/ar…
Michael Wilkinson retweeted
Are you attending #AAFPFMX in Nashville? Join Lilly Medical on Tuesday, October 20, for the Lilly Lp(a) Trailblazing Session. Hear from a patient advocate and physician experts on evolving cardiovascular risk assessment in primary care.
Learn more: e.lilly/FMX26
Michael Wilkinson retweeted
In case you missed it: the Lipid Insights × The Tell-Tale Heart collaboration episode is live and worth your time!🎙️ @pharmacy_times
From the 2026 Dyslipidemia Guideline in practice to the role of the pharmacy team in lipid management and patient outcomes, host Craig J. Beavers, PharmD and Michael J. Wilkinson, MD, FNLA cover the latest intersections of cardiovascular pharmacy and lipidology.
🎧 Listen on Spotify, Apple Podcasts, or wherever you get your podcasts.
📺 Prefer video? Watch on YouTube: ow.ly/gUSw50ZWyla
@beaverspharmd @mwilkinsonmd
#Lipidology #CardiovascularPharmacy #DyslipidemiaGuidelines #CardiometabolicHealth
Michael Wilkinson retweeted
Part 1: A conversation with @MWilkinsonMD from UCSD on Lipoprotein(a). In this first part we talk about what is Lp(a), when to measure, and what should we do if the values are elevated (> 125 nmol/L or >50 mg/dL). In Part 2, we will talk about Horizon Lp(a) and landscape of therapeutics
@nationallipid @ASPCardio @AJPCardio
Michael Wilkinson retweeted
Part 2: The latest news on Lp(a) therapeutics: preliminary results of Horizon Lp(a) are negative, what now? Insights from @MWilkinsonMD #NLAFallUpdates
@nationallipid @ASPCardio @AJPCardio
Michael Wilkinson retweeted
On September 4, 2026, Novartis announced the topline results of its phase 3 Lp(a)HORIZON trial. Novartis shared that while pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the trial failed to reduce the risk of major adverse cardiovascular events (MACE). The full clinical trial results are not yet available.
Lp(a) remains an important and independent risk factor for ASCVD. Clinicians and patients should continue to measure Lp(a).
The Lp(a)HORIZON trial is the first of several clinical trials underway to test the impact of lowering Lp(a) on reducing MACE.
Read the NLA's full statement & access Lp(a) resources at lipid.org/resource/top-line-….
Michael Wilkinson retweeted
Patients with autoimmune or inflammatory disease had 22% higher odds of elevated Lp(a) vs controls. New in #JACCAdvances: jacc.org/doi/10.1016/j.jacad… #cvLipids @MWilkinsonMD
Michael Wilkinson retweeted
Novartis announces Lp(a)HORIZON Phase III topline results
“did not meet its primary endpoint”
There will be a lot to unpack here globenewswire.com/news-relea…
New in @JACCJournals: 49,431 patients across 5 UC health systems: 🔥autoimmune/inflammatory disease was associated with 22% higher odds of Lp(a) >50 mg/dL
Congrats @ROcher_MD!
@PamTaubMD @hsbhatia @MattRamsisMD @UCSDCardiology @nationallipid @Bweber04
doi.org/10.1016/j.jacadv.202…
Michael Wilkinson retweeted
How Lp(a) Shapes Coronary Plaque and Cardiovascular Risk - Michael Wilkinson (@MWilkinsonMD)
@hsbhatia
hemostasistoday.com/science/…
#HemostasisToday
State-of-the-art review @SpringerCurRpts Lp(a) + coronary imaging:
⚫️CAC: more CAC, +progression; mixed results
⚫️CCTA: ⬆️plaque, ⬆️high-risk features
⚫️OCT/IVUS: ⬆️vulnerable plaque, faster progression
doi.org/10.1007/s11883-026-0…
@hsbhatia @PamTaubMD @lipiddoc @khurramn1 @BudoffMd
Michael Wilkinson retweeted
So proud of our @UCSDCardiology team, ranked #15 in the nation for cardiology by U.S. News! Congrats also to @UCSDHealth on being #1 in California and Top 20 in the nation.
health.ucsd.edu/news/press-r… @UCSDMedSchool
@UCSDCardFellows @loridanielsmd @EricAdler17 @pattymaysent @DrAlexKhalessi @JonHsuMD @MWilkinsonMD @hsbhatia @DrLoomba @AntoinetteBirs @MattRamsisMD @laithalsh @EugeneGolts
🔥New review w/ 🌟 @sawyeraygani in @LipidJournal:
The full, up-to-date Lp(a)-lowering landscape + a complete phase 3 trial tracker
doi.org/10.1016/j.jacl.2026.…
@nationallipid @ASPCardio @PamTaubMD @hsbhatia @CBallantyneMD @DineshKalra @DrMichaelShapir @FamilyHeartFdn @MarlysLPA
Michael Wilkinson retweeted
Excited to share our new case report, led by Kyla Laing, that showed that TRE can improve nighttime glucose in adults who had been on GLP-1 for years! @PamTaubMD @MWilkinsonMD @SatchinPanda frontiersin.org/journals/cli…
Michael Wilkinson retweeted
Congratulations to our 2026 #NLASessions Abstract Award Winners! The research presented this year was nothing short of extraordinary, and a true reflection of the exciting developments shaping the future of lipidology.
🏆 Hunninghake Familial Hypercholesterolemia (FH) Award
Jose Lopez, MS
"Early Detection of Familial Hypercholesterolemia Through Point of Care Testing in 2-Year-Olds"
🥇 1st Place
Jianing Li, MD
"GLP-1 Receptor Agonists Rarely Cause Acute Pancreatitis but Induce Noninflammatory Acinar Hypertrophy, Pancreatic Enlargement and Mild Lipase Leak"
🥈 2nd Place
Jeremy Skinner, BS
"Accelerating Lipoprotein(a) Testing in Community Health Centers Through Quality Improvement and Education"
🥉 3rd Place
Christie Ballantyne, MD @CBallantyneMD
"Pooled Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, Across Two Phase 3 Trials: CORALreef Lipids and CORALreef HeFH"
Explore their research and the full Poster Hall at the link below.👇
🔗 lipidjournal.com/issue/S1933…
#Lipidology #CardiometabolicHealth #PreventiveCardiology #Research
Michael Wilkinson retweeted
Time‑restricted eating in the TREAD RCT, a 10‑hour eating window led to greater weight loss, healthier body composition, and downregulation of proinflammatory adipose genes versus standard care.
onlinelibrary.wiley.com/doi/…
🎉Congrats to my mentee Kaden Hubly, third year med student @UCSDMedSchool - two posters @nationallipid 2026 Scientific Sessions - examining high Lp(a) and very premature ASCVD events (18-45 yrs)
@PamTaubMD @hsbhatia @MattRamsisMD @DineshKalra @DrNathanWong @CBallantyneMD
Fantastic representation of the Pacific Lipid Association (PLA)💪at 2026 Scientific Sessions @nationallipid - join the PLA if you’re a lipid / prevention enthusiast from the West coast / Pacific Region 🌴🌊🌳🏔️🌲
@hsbhatia @ianriddockmd @carolkirkpat3 @JamalRanaMD @DrNathanWong
🎉Our RCT in @ObesitySociety
10-hr TRE ➡️ ~3× more wt loss vs. standard of care in obesity over 12 wks
Exploratory adipose RNA-seq: ⬇️ inflammation
Meal timing matters
doi.org/10.1002/oby.70228
@PamTaubMD @SatchinPanda @EmilyManoogian @DrKristaVarady @salkinstitute @UCSDHealth
